Evidence network for deaths_(OS)

2IMpower-131 (ACnP), 2020 IMpower-130 (WT), 20191IMpower-130 (all population), 20193CheckMate 017, 2015 CheckMate 057, 2015 CheckMate 078, 20192CheckMate 026 (PDL1>5%), 2016 CheckMate 026 (PDL1>1%), 20162KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 KEYNOTE-010 (P: 2mg/kg), 20161KEYNOTE-021, 20163POPLAR, 2016 OAK (all population), 2016 OAK (PDL1 TC 1/2/3), 20163IMpower-110 (TC3 or IC3), 2020 IMpower-110 (TC2/3 or IC2/3), 2020 IMpower-110 (TC1/2/3 or IC1/2/3), 20201CA184-104, 20172KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 KEYNOTE-010 (P:10 mg/kg), 20164KEYNOTE-024 (PDL1>50%), 2016 KEYNOTE-042 (PDL1>50%), 2019 KEYNOTE-042 (PDL1>20%), 2019 KEYNOTE-042 (PDL1>1%), 20191PACIFIC, 20173MYSTIC (D ; PDL1>25%), 2020 MYSTIC (D ; all population), 2020 ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 20201CheckMate 9LA, 20211CheckMate 227 (NI vs C ; PDL1>1%), 20182KEYNOTE-407, 2018 KEYNOTE-189, 20182IMpower-150 (ABCP vs BPC WT), 2018 IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 20181IMpower-132 (WT), 02JAVELIN Lung 200 (PDL1 >1%), 2018 JAVELIN Lung 200 (all population), 20181CAURAL (EXPLORATORY), 20191CheckMate 227 (NC vs C ; PDL1<1%), 20181ORIENT-11, 20201IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 20183MYSTIC (DT ; PDL1>25%), 2020 MYSTIC (DT ; all population), 2020 ARCTIC (DT ; study B ; PDL1<25%), 20201KEYNOTE-598, 20202EMPOWER lung1 (PDL1>50%), 2021 EMPOWER lung1 (all population), 20211CodeBreaK 200, 2022docetaxelpemetrexed plus platinplacebo plus SoCStandard of Care (SoC)placebobevacizumab plus carboplatin and paclitaxelcarboplatin plus nab-paclitaxelosimertinibgemcitabine plus platinpaclitaxel plus carboplatinatezolizumab plus carboplatin plus nab-paclitaxelpembrolizumab plus placebochemotherapyno control (uncontrolled study)nivolumab alonepembrolizumab (2mg/kg)pembrolizumab and pemetrexed plus platinatezolizumab aloneipilimumab plus SoCpembrolizumab alonedurvalumab alonenivolumab plus ipilimumabpembrolizumab plus SoCatezolizumab plus bevacizumab plus carboplatin plus paclitaxelatezolizumab plus pemetrexed and platinavelumab alonedurvalumab plus osimertinibnivolumab plus SoCnivolumab plus ipilimumab plus SoCsintillimab plus SoCatezolizumab plus carboplatin plus paclitaxelpembrolizumab (10mg/kg)durvalumab plus tremelimumabpembrolizumab plus ipilimumabTislelizumabcemiplimabcapmatinibpralsetinibentrectinibsotorasibtrametinib plus dabrafenibselpercatiniblarotrectinibdirect evidencenetwork meta-analysis
T vs. C docetaxelpemetrexed plus platinplacebo plus SoCStandard of Care (SoC)placebobevacizumab plus carboplatin and paclitaxelcarboplatin plus nab-paclitaxelosimertinibgemcitabine plus platinpaclitaxel plus carboplatinatezolizumab plus carboplatin plus nab-paclitaxelpembrolizumab plus placebochemotherapyno control (uncontrolled study)nivolumab alonepembrolizumab (2mg/kg)pembrolizumab and pemetrexed plus platinatezolizumab aloneipilimumab plus SoCpembrolizumab alonedurvalumab alonenivolumab plus ipilimumabpembrolizumab plus SoCatezolizumab plus bevacizumab plus carboplatin plus paclitaxelatezolizumab plus pemetrexed and platinavelumab alonedurvalumab plus osimertinibnivolumab plus SoCnivolumab plus ipilimumab plus SoCsintillimab plus SoCatezolizumab plus carboplatin plus paclitaxelpembrolizumab (10mg/kg)durvalumab plus tremelimumabpembrolizumab plus ipilimumabTislelizumabcemiplimabcapmatinibpralsetinibentrectinibsotorasibtrametinib plus dabrafenibselpercatiniblarotrectinib
docetaxel---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pemetrexed plus platinNA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
placebo plus SoCNANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Standard of Care (SoC)NANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
placeboNANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
bevacizumab plus carboplatin and paclitaxelNANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
carboplatin plus nab-paclitaxelNANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
osimertinibNANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
gemcitabine plus platinNANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
paclitaxel plus carboplatinNANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
atezolizumab plus carboplatin plus nab-paclitaxelNANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pembrolizumab plus placeboNANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
chemotherapyNANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
no control (uncontrolled study)NANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
nivolumab aloneNANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
pembrolizumab (2mg/kg)NANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANA
pembrolizumab and pemetrexed plus platinNANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANA
atezolizumab aloneNANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANA
ipilimumab plus SoCNANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANA
pembrolizumab aloneNANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANA
durvalumab aloneNANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANA
nivolumab plus ipilimumabNANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANA
pembrolizumab plus SoCNANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANA
atezolizumab plus bevacizumab plus carboplatin plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANA
atezolizumab plus pemetrexed and platinNANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANA
avelumab aloneNANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANA
durvalumab plus osimertinibNANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANA
nivolumab plus SoCNANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANA
nivolumab plus ipilimumab plus SoCNANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANA
sintillimab plus SoCNANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANA
atezolizumab plus carboplatin plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANA
pembrolizumab (10mg/kg)NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANA
durvalumab plus tremelimumabNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANA
pembrolizumab plus ipilimumabNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANA
TislelizumabNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANA
cemiplimabNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANA
capmatinibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANA
pralsetinibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANA
entrectinibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANA
sotorasibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANA
trametinib plus dabrafenibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANA
selpercatinibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NA
larotrectinibNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 1402 result logic